Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP).

Etsuko Aoki, MD, PhD, Hagop Kantarjian, MD, Susan O’Brien, MD, Mary Beth Rios, R.N., Farhad Ravandi, MD, Srdan Verstovsek, MD, Guillermo Garcia-Manero, MD, Jianqin Shan, PhD, Jorge Cortes, MD

Blood (2005) 106 (11): 1103.

https://doi.org/10.1182/blood.V106.11.1103.1103

Published: 2005

Journal Articles

Conception and Pregnancy in Patients (pts) with Chronic Myeloid Leukemia (CML) Receiving Therapy with Imatinib Mesylate (IM).

Pat Ault, APN, Hagop Kantarjian, MD, Susan O’Brien, MD, Charles Koller, MD, Stefan Faderl, MD, Emil J. Freireich, MD, Mary Beth Rios, R.N., Jorge Cortes, MD

Blood (2005) 106 (11): 1104.

https://doi.org/10.1182/blood.V106.11.1104.1104

Published: 2005

Journal Articles

Chromosomal Abnormalities in Philadelphia Chromosome (Ph)-Negative Metaphases Appearing during Imatinib Mesylate (IM) Therapy in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase.

Elias Jabbour, MD, Hagop Kantarjian, MD, Susan O’Brien, MD, Srdan Verstovsek, MD, Guillermo Garcia-Manero, MD, Mary Beth Rios, R.N, Jorge Cortes, MD

Blood (2005) 106 (11): 1090.

https://doi.org/10.1182/blood.V106.11.1090.1090

Published: 2005

Journal Articles

Outcome of Salvage Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Failed Imatinib after Developing BCR-ABL Kinase Mutation.

Elias Jabbour, MD, Hagop Kantarjian, MD, Moshe Talpaz, MD, Dan Jones, MD, PhD., Susan O’Brien, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, Mary Beth Rios, R.N., Jorge Cortes, MD

Blood (2005) 106 (11): 1092.

https://doi.org/10.1182/blood.V106.11.1092.1092

Published: 2005

Journal Articles

Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.

Jorge Cortes, M.D., Moshe Talpaz, M.D., Susan O’Brien, M.D., Dan Jones, M.D., Ph.D., Raja Luthra, Ph.D., Guillermo Garcia-Manero, M.D., Francis Giles, M.D., Jenny Shan, Ph.D., Srdan Verstovsek, M.D., Ph.D., Mary Beth Rios, R.N., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 272.

https://doi.org/10.1182/blood.V104.11.272.272

Published: 2004

Journal Articles

Sudden Blastic Transformation (SBT) in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate.

Marieberta Vidal, M.D., Hagop Kantarjian, M.D., Susan O’Brien, M.D., Mary Beth Rios, R.N., Srdan Verstovsek, M.D., Jorge Cortes, M.D.

Blood (2004) 104 (11): 2930.

https://doi.org/10.1182/blood.V104.11.2930.2930

Published: 2004

Journal Articles

Imatinib Mesylate for Patients (pts) with Hypereosinophilic Syndrome (HES) and Systemic Mastocytosis (SM): A Phase II Trial.

Elias Jabbour, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Dan Jones, Ph.D., M.D., Susan O’Brien, M.D., Raja Luthra, Ph.D., Farhad Ravandi-Kashani, M.D., William Wierda, M.D., Francis Giles, M.D., Mary Beth Rios, R.N., Jorge Cortes, M.D.

Blood (2004) 104 (11): 4752.

https://doi.org/10.1182/blood.V104.11.4752.4752

Published: 2004

Journal Articles

Survival Advantage for Patients (pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Treated with Imatinib.

Jorge Cortes, M.D., Moshe Talpaz, M.D., Susan O’Brien, M.D., Guillermo Garcia-Manero, M.D., Farhad Ravandi-Kashami, M.D., Francis Giles, M.D., Stefan Faderl, M.D., William Wierda, M.D., Jianqin Shan, Ph.D., Mary Beth Rios, R.N., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 1006.

https://doi.org/10.1182/blood.V104.11.1006.1006

Published: 2004

Journal Articles

Long-Term Incidence and Outcome of BCR-ABL Mutations in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate - P-Loop Mutations Are Not Associated with Worse Outcome.

Elias Jabbour, M.D., Hagop Kantarjian, M.D., Dan Jones, Ph.D., M.D., Susan O’Brien, M.D., Raja Luthra, Ph.D., Guillermo Garcia-Manero, M.D., Francis Giles, M.D., Mary Beth Rios, R.N., Srdan Verstovsek, M.D., Jorge Cortes, M.D.

Blood (2004) 104 (11): 1007.

https://doi.org/10.1182/blood.V104.11.1007.1007

Published: 2004

Journal Articles

Is the Proposed World Health Organization (WHO) Classification for Chronic Myeloid Leukemia (CML) of Clinical Value in the Imatinib Era?.

Jorge Cortes, M.D., Susan O’Brien, M.D., Guillermo Garcia-Manero, M.D., Stefan Faderl, M.D., Jenny Shan, Ph.D., Francis Giles, M.D., Srdan Verstovsek, M.D., Mary Beth Rios, R.N., Moshe Talpaz, M.D., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 1014.

https://doi.org/10.1182/blood.V104.11.1014.1014

Published: 2004

Journal Articles

High-Dose Imatinib Mesylate Treatment in Patients (Pts) with Previously Untreated Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML).

Jorge Cortes, M.D., Moshe Talpaz, M.D., Susan O’Brien, M.D., Francis Giles, M.D., Mary Beth Rios, R.N., Laurie Levtak, M.D., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 999.

https://doi.org/10.1182/blood.V104.11.999.999

Published: 2004

NARROW

Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP).

Conception and Pregnancy in Patients (pts) with Chronic Myeloid Leukemia (CML) Receiving Therapy with Imatinib Mesylate (IM).

Chromosomal Abnormalities in Philadelphia Chromosome (Ph)-Negative Metaphases Appearing during Imatinib Mesylate (IM) Therapy in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase.

Outcome of Salvage Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Failed Imatinib after Developing BCR-ABL Kinase Mutation.

Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.

Sudden Blastic Transformation (SBT) in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate.

Imatinib Mesylate for Patients (pts) with Hypereosinophilic Syndrome (HES) and Systemic Mastocytosis (SM): A Phase II Trial.

Survival Advantage for Patients (pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Treated with Imatinib.

Long-Term Incidence and Outcome of BCR-ABL Mutations in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate - P-Loop Mutations Are Not Associated with Worse Outcome.

Is the Proposed World Health Organization (WHO) Classification for Chronic Myeloid Leukemia (CML) of Clinical Value in the Imatinib Era?.

High-Dose Imatinib Mesylate Treatment in Patients (Pts) with Previously Untreated Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only